# Patent

## Title
Anti-microbial peptides and methods of use thereof

## Abstract

Anti-microbial peptides and methods of use are provided.

## Background
This application is a §371 application of PCT/US2012/066085, filed Nov. 20, 2012, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 61/561,990, filed on Nov. 21, 2011. The foregoing application are incorporated by reference herein.


This invention was made with government support under 1R56 AI081975-01A2 and 1R21 AI082689 awarded by the National Institutes of Health. The government has certain rights in the invention.


FIELD OF THE INVENTION
The present invention relates to the field of antimicrobial peptides and the treatment of microbial infections. More specifically the invention provides anti-MRSA peptides, methods of identifying the same, and methods of using such peptides for the treatment of MRSA infections.
BACKGROUND OF THE INVENTION
In the United States, methicillin-resistant Staphylococcus aureus (MRSA) caused 94,360 serious infections and 18,650 deaths in 2005. The number of annual deaths caused by MRSA infection is now higher than that caused by HIV/AIDS (Klevens et al. (2007) Public Health Rep., 122:160-166). Bacterial resistance rendered traditional antibiotics ineffective, adding an unwanted burden to medical care. As a consequence, it is critical to develop a new generation of antibiotics that can eliminate superbugs such as MRSA by a mechanism different from those of traditional antibiotics.
SUMMARY OF THE INVENTION
In accordance with one aspect of the instant invention, anti-microbial peptides are provided. In a particular embodiment, the anti-microbial peptide has at least 90% homology with SEQ ID NO: 63 or any anti-microbial peptide disclosed herein. Compositions comprising at least one anti-microbial peptide of the instant invention and at least one pharmaceutically acceptable carrier are also provided. The compositions may further comprise at least one other anti-microbial compound (e.g., antibiotic).
In accordance with another aspect of the instant invention, method for inhibiting, treating, and/or preventing a microbial infection in a subject are provided. The methods comprise administering to a subject at least one peptide of the instant invention, particularly as a composition with a carrier. In a particular embodiment, the methods further comprise the administration at least one other anti-microbial treatment, such as the administration of at least one additional antibiotic.
In accordance with another aspect of the instant invention, methods for creating anti-microbial peptides are provided.



BRIEF DESCRIPTIONS OF THE DRAWING
FIG. 1 shows the database filtering technology (FIG. 1A) and the determination of peptide length (FIG. 1B), amino acids (FIG. 1C), charge (FIG. 1D), hydrophobic content (FIG. 1E), and structure type (FIG. 1F). Key parameters required for peptide design were obtained stepwise as depicted in FIG. 1A. The final peptide designed in this manner was referred to as DFTamP1 (i.e. database filtering technology-designed antimicrobial peptide 1). FIG. 1G shows that residues G, K, and S are shared frequently occurring residues in natural AMPs. Plotted are sequence profiles for 44 lantibiotics from bacteria, 131 cyclotides from plants, and 75 temporins from amphibians. Although these peptides adopt different structural scaffolds and kill bacteria in different mechanisms, G, S, and K are abundant in these three peptide groups from different life kingdoms, indicative of their universal importance in natural AMPs.
FIG. 2 shows the structure and activity of DFTamP1. Shown are transmission electron microscopy images of MRSA USA300 before (FIG. 2A) and after peptide treatment (FIG. 2B), rapid killing of the 108 colony-forming units of S. aureus USA300 by 2×MIC followed by flow cytometry (FIG. 2C), and NMR studies (FIGS. 2D and 2E) that enabled one to view the active conformation of the peptide (FIGS. 2F-2I). DFTamP1 has the highest content of leucines (61.5%) compared to natural temporins. Despite this difficulty, the cross peaks of these leucines are resolved in the natural abundance 2D 1H and 15N correlated NMR spectrum of DFTamP1 in complex with 40-fold deuterated sodium dodecyl sulfate at 25° C. and pH 5.4 (FIG. 2E). Displayed structural views of membrane-bound DFTamP1 are superimposed backbone structures (FIG. 2F), a ribbon diagram indicating a clear segregation of hydrophilic (residues S4, S7, and K11) and hydrophobic leucine side chains (FIG. 2G), potential surface (FIG. 2H), and local structure at the C-terminus indicating hydrogen bonding between the C-terminal amide NH2 and the carbonyl atom of residue L9 of the peptide (FIG. 2I). FIG. 2J shows that the rapid killing of S. aureus USA300 by DFTamP1 is also supported by traditional killing kinetics. The experiments were set up in the same manner as the antibacterial assays above with the following additions. Bacteria (105 colony forming units of S. aureus USA300) were treated at a peptide level of 2×MIC). Aliquots were taken at 15, 30, 50, 90, and 120 minutes, plated after 100-fold dilution, and the colonies were counted after overnight incubation at 37° C.
FIG. 3 shows the real time killing of S. aureus USA300 by DFTamP1 (FIG. 3A) and its mutant DFTamP1-pv (FIG. 3B). In the plots, bacterial growth or killing curves treated with 0, 1, 2, or 8×MICs of DFTamP1 are shown. For clarity, the curve at 4×MIC was not displayed since it is similar to that of 8×MIC. The microplate was incubated in a shaker at 100 rpm and 37° C. This figure indicates that the designed peptide DFTamP1 is able to lyse and inhibit MRSA USA300 at 8×MICs, whereas DFTamP1-pv was unable to even at four-fold the corresponding concentrations of DFTamP1.
FIG. 4 shows a stability comparison of the L- and D-forms of temporin-PTa in the presence of chymotrypsin. A solution (100 μl) of the peptide and 12.5 μM chymotrypsin (peptide/protein molar ratio, 40:1) in 10 mM PBS buffer (pH 8) was incubated at 37° C. Aliquots (10 μl) of the reaction solutions were taken at 0, 2, 4, and 22 hours and immediately mixed with 20 μl of 2×SDS loading buffer to stop the reaction. For the gel analysis, 10 μl of each sample was loaded to the well of a 5% stacking/18% resolving tricine gel. The samples in the lanes are: 1, protein marker; 2, temporin-PTa L-form at 0 hour; 3, 2 hours; 4, 4 hours; 5, 22 hours; 6, temporin-PTa D-form at 0 hour; 7, 2 hours; 8, 4 hours; 9, 22 hours. In the gel, the bands for the peptide and chymotrypsin were indicated with large and small arrows, respectively. Note that the peptide bands were not detected in lanes 3-5 due to protease cleavage but remained essentially constant in lanes 7-9. This figure indicates that in the presence of chymotrypsin, the L-form of temporin-PTa was degraded within 2 hours (lanes 3-5), while the D-form was stable for at least 22 hours (lanes 7-9).
FIG. 5 shows the impact of DASamP1 on S. aureus biofilms in vivo. Mice received DASamP1 injections at 0, 24, and 48 hours following S. aureus infection and were sacrificed at days 3 (FIGS. 5A, 5B) and 14 (FIGS. 5C, 5D) following infection, whereupon catheters (FIGS. 5A, 5C) and surrounding host tissue (FIGS. 5B, 5D) were recovered to quantitate bacterial burdens. Results are expressed as the number of cfu per ml for catheters or cfu per mg tissue to correct for differences in tissue sampling size. Significant differences inn bacterial burdens between PBS and peptide-treated mice are denoted by asterisk (*, p<0.05) with results presented from individual animals with bars representing the mean of each group.
FIG. 6 shows the hydrophobic defect (pointed by an arrow) in the potential surface of GF-17d3 determined by NMR spectroscopy (Li et al. (2006) J. Am. Chem. Soc. 128:5776-5785). This structure forms the basis for designing various antimicrobial peptides by filling this structural defect with a variety of hydrophobic groups.
FIG. 7 shows that the LL-37 peptide derivative D128A demonstrates long-term efficacy at reducing S. aureus biofilm infections in vivo. C57BL/6 mice received 4 injections (200 μg each) of D128A or PBS vehicle at 12, 24, and 48 hours following S. aureus infection, whereupon bacterial titers associated with infected catheters and surrounding tissues were quantitated at day 3 or 14 post-infection. Each symbol represents data from an individual animal. Significant differences are denoted by asterisks (*, p<0.001).



DETAILED DESCRIPTION OF THE INVENTION
Natural antimicrobial peptides are promising candidates to be developed into a new generation of antimicrobials due to their potency for millions of years. To effectively exploit these molecules, the antimicrobial peptide database (aps.unmc edu/AP) has been constructed. A unique approach dubbed database filtering technology (DFT) is provided herein that enables one to design ab initio potent anti-MRSA peptides systematically. DFTamP1, the first antimicrobial peptide designed using DFT, has numerous desired features: short (cost effective to synthesize), stable (the D-form is resistant to proteases), and effective in vivo. Additionally, further compounds were obtained by combining the findings from previous database screens and the current ab initio design. Therefore, the instant invention covers both novel methods for peptide design and novel anti-MRSA compounds.
I. Definitions
The term “isolated” is not meant to exclude artificial or synthetic mixtures with other compounds or materials, or the presence of impurities that do not interfere with the fundamental activity, and that may be present, for example, due to incomplete purification, or the addition of stabilizers.
The term “substantially pure” refers to a preparation comprising at least 50-60% by weight of a given material (e.g., nucleic acid, oligonucleotide, protein, etc.). More preferably, the preparation comprises at least 75% by weight, and most preferably 90-95% or more by weight of the given compound. Purity is measured by methods appropriate for the given compound (e.g. chromatographic methods, agarose or polyacrylamide gel electrophoresis, HPLC analysis, and the like).
“Pharmaceutically acceptable” indicates approval by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
A “carrier” refers to, for example, a diluent, adjuvant, preservative (e.g., Thimersol, benzyl alcohol), anti-oxidant (e.g., ascorbic acid, sodium metabisulfite), solubilizer (e.g., TweenTM 80, Polysorbate 80), emulsifier, buffer (e.g., Tris HCl, acetate, phosphate), antimicrobial, bulking substance (e.g., lactose, mannitol), excipient, auxiliary agent or vehicle with which an active agent of the present invention is administered. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin. Water or aqueous saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E.W. Martin (Mack Publishing Co., Easton, Pa.); Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 20th Edition, (Lippincott, Williams and Wilkins), 2000; Liberman, et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Kibbe, et al., Eds., Handbook of Pharmaceutical Excipients (3rd Ed.), American Pharmaceutical Association, Washington, 1999.
A “therapeutically effective amount” of a compound or a pharmaceutical composition refers to an amount effective to prevent, inhibit, treat, and/or lessen the symptoms of a particular disorder or disease. The treatment of a microbial infection (e.g., S. aureus infection) herein may refer to an amount sufficient to inhibit microbial growth or kill the microbe and/or curing, relieving, and/or preventing the microbial infection, the symptom of it, or the predisposition towards it.
As used herein, the term “antibiotic” refers to antimicrobial agents for use in mammalian, particularly human, therapy. Antibiotics include, without limitation, beta-lactams (e.g., penicillin, ampicillin, oxacillin, cloxacillin, methicillin, and cephalosporin), carbacephems, cephamycins, carbapenems, monobactams, aminoglycosides (e.g., gentamycin, tobramycin), glycopeptides (e.g., vancomycin), quinolones (e.g., ciprofloxacin), moenomycin, tetracyclines, macrolides (e.g., erythromycin), fluoroquinolones, oxazolidinones (e.g., linezolid), lipopetides (e.g., daptomycin), aminocoumarin (e.g., novobiocin), co-trimoxazole (e.g., trimethoprim and sulfamethoxazole), lincosamides (e.g., clindamycin and lincomycin), polypeptides (e.g., colistin), and derivatives thereof.
II. Peptides
The anti-microbial peptides of the present invention may be prepared in a variety of ways, according to known methods. The anti-microbial peptides of the instant invention may also be chemically synthesized. For example, the peptides may be synthesized using a liquid-phase method or solid-phase method. The chemically synthesized peptides may then be purified (e.g., by HPLC).
The anti-microbial peptides may also be purified from appropriate sources (e.g., bacterial or animal cultured cells or tissues, optionally transformed) by immunoaffinity purification. The availability of nucleic acid molecules encoding the anti-microbial peptides enables production of the protein using in vitro expression methods and cell-free expression systems known in the art.
Larger quantities of anti-microbial peptides may be produced by expression in a suitable prokaryotic or eukaryotic system. For example, part or all of a DNA molecule encoding for an anti-microbial peptide may be inserted into a plasmid vector adapted for expression in a bacterial cell, such as E. coli. Such vectors comprise the regulatory elements necessary for expression of the DNA in the host cell positioned in such a manner as to permit expression of the DNA in the host cell. Such regulatory elements required for expression include promoter sequences, transcription initiation sequences and, optionally, enhancer sequences.
Anti-microbial peptides produced by gene expression in a recombinant prokaryotic or eukaryotic system may be purified according to methods known in the art. A commercially available expression/secretion system can be used, whereby the recombinant protein is expressed and thereafter secreted from the host cell, and readily purified from the surrounding medium. If expression/secretion vectors are not used, an alternative approach involves purifying the recombinant protein by affinity separation, such as by immunological interaction with antibodies that bind specifically to the recombinant protein or nickel columns for isolation of recombinant proteins tagged with 6-8 histidine residues at their N-terminus or C-terminus. Alternative tags may comprise the FLAG epitope or the hemaglutinin epitope. Such methods are commonly used by skilled practitioners.
Anti-microbial peptides of the invention, prepared by the aforementioned methods, may be analyzed and verified according to standard procedures. For example, such protein may be subjected to amino acid sequence analysis, according to known methods.
Anti-microbial peptides are provided in the examples hereinbelow. Indeed, the instant invention encompasses any anti-microbial peptide described herein and their derivatives/variants, e.g., those derivatives/variants generated by sequence truncation, mutation, reversal, or shuffling. For example, the anti-microbial peptide of the instant invention may comprise any one of SEQ ID NOs: 1-63, particularly SEQ ID NOs: 1-9 and 22-63. As stated hereinbelow, the peptides may or may not comprise modifications (e.g., amidation or D-amino acids) and the provided SEQ ID NOs may encompass the base sequence with or without the modifications. In a particular embodiment, the anti-microbial peptide of the instant invention comprises SEQ ID NO: 1 (DFTamP1), SEQ ID NO: 2 (DFTamP1-p), SEQ ID NO: 5 (temporin-PTa), SEQ ID NO: 6 (temporin-PTa, D-form), SEQ ID NO: 7 (temporin-PTa6L), SEQ ID NO: 8 (temporin-PTa8L), SEQ ID NO: 9 (DASamP1), SEQ ID NO: 34 (piscidin 1), SEQ ID NO: 37 (lycotoxin I), SEQ ID NO: 40 (maculatin 1.3), SEQ ID NO: 43 (ascaphin-8), SEQ ID NO: 47 (DASamP2), SEQ ID NO: 48 (DASamPS), SEQ ID NO: 50 (DASamPS), SEQ ID NO: 51 (DASamP6), SEQ ID NO: 52 (DASamP7), SEQ ID NO: 53 (DASamP8), SEQ ID NO: 59 (A128A), SEQ ID NO: 60 (B128A), SEQ ID NO: 61 (C128A), or SEQ ID NO: 62 (D128A). In a particular embodiment, the anti-microbial peptide of the instant invention (particularly in methods of inhibiting a microbial infection) comprises SEQ ID NO: 5 (temporin-PTa), SEQ ID NO: 34 (piscidin 1), SEQ ID NO: 37 (lycotoxin I), SEQ ID NO: 40 (maculatin 1.3), or SEQ ID NO: 43 (ascaphin-8), particularly SEQ ID NO: 5 (temporin-PTa) or SEQ ID NO: 40 (maculatin 1.3). In another embodiment, the anti-microbial peptide of the instant invention comprises SEQ ID NO: 1 (DFTamP1), SEQ ID NO: 6 (temporin-PTa, D-form), SEQ ID NO: 7 (temporin-PTa6L), SEQ ID NO: 8 (temporin-PTa8L), SEQ ID NO: 9 (DASamP1), SEQ ID NO: 47 (DASamP2), SEQ ID NO: 51 (DASamP6), SEQ ID NO: 52 (DASamP7), SEQ ID NO: 53 (DASamP8), or SEQ ID NO: 62 (D128A). In another embodiment, the anti-microbial peptide of the instant invention comprises SEQ ID NO: 1, 2, 6, 7, 8, 9, 48, 50, 51, 52, 53, 59, 60, 61, or 62. In another embodiment, the anti-microbial peptide of the instant invention comprises SEQ ID NO: 1, 2, 6, 7, 8, 59, 60, 61, or 62. In a particular embodiment, the anti-microbial peptide of the instant invention comprises SEQ ID NO: 58 or 63. In a particular embodiment, the anti-microbial peptide of the instant invention comprises SEQ ID NO: 1 (DFTamP1).
In a particular embodiment of the instant invention, the peptide comprises the sequence: X1X2X3X4LLX5LLX6X7LL (SEQ ID NO: 63), wherein X1-X7 are any amino acid or derivative thereof. In a particular embodiment, X1, X2, X3, and X4 comprise two consecutive hydrophobic amino acids (e.g., Ile, Leu, Val, Trp, or Phe) and two hydrophilic amino acids (e.g., Asn, Ser, Gln, Thr, Gly, Pro, H is, Lys, or Arg) and X5, X6, and X7 are each a hydrophilic amino acid.
In one embodiment, X4 is Ser, X7 is Lys, X1, X2, and X3 comprise two consecutive hydrophobic amino acids, particularly Leu or Phe. In a particular embodiment, the non-hydrophobic amino acid of X1, X2, and X3 is Gly. In a particular embodiment, X5 is a polar or positively charged amino acid, particularly Ser or Lys. In a particular embodiment, X6 is Pro or Gly.
In another embodiment, X1 and X2 are Leu and X3-X7 are hydrophilic amino acids. In a particular embodiment, X3 is Gly. In a particular embodiment, X4 is a polar or positively charged amino acid, particularly Ser or Lys. In a particular embodiment, X5 is a polar or positively charged amino acid, particularly Ser or Lys. In a particular embodiment, X6 is Pro or Gly. In a particular embodiment, X7 is a polar or positively charged amino acid, particularly Ser or Lys.
In yet another embodiment, X1 and X2 are Phe and X3-X7 are hydrophilic amino acids. In a particular embodiment, X3 is Gly. In a particular embodiment, X4 is a polar or positively charged amino acid, particularly Ser or Lys. In a particular embodiment, X5 is a polar or positively charged amino acid, particularly Ser or Lys. In a particular embodiment, X6 is Pro or Gly. In a particular embodiment, X7 is a polar or positively charged amino acid, particularly Ser or Lys.
In yet another embodiment, at least one of the Leu residues of the peptide of SEQ ID NO: 63 are replaced with another hydrophobic amino acid (e.g., Ile, Leu, Val, Trp, or Phe).
In a particular embodiment of the instant invention, the peptide comprises the sequence: GX1KRLVQRLKDX2LRNLV (SEQ ID NO: 58), wherein X1 and X2 are any amino acid or derivative, particularly any hydrophobic amino acids (e.g., Ile, Leu, Val, Trp, or Phe). In a particular embodiment, the Leu at positions 5, 9, and 13 are D-amino acids.
The amino acid sequence of the anti-microbial peptide of the instant invention may have at least 75%, 80%, 85%, 90%, 95%, 97%, 99%, or 100% homology with the above sequences, particularly at least 90% homology (e.g., the sequence may contain additions, deletions, and/or substitutions). In a particular embodiment, the anti-microbial peptide of the instant invention may extend beyond the above sequences at the amino and/or carboxy terminus by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, particularly by 1, 2, 3, 4, or 5 amino acids, particularly by 1, 2, or 3 amino acids. In yet another embodiment, the anti-microbial inhibitory peptides of the instant invention may also be in reverse orientation. In a particular embodiment, the peptides of the instant invention have fewer than about 50 amino acids, fewer than about 25 amino acids, fewer than about 20 amino acids, fewer than about 17 amino acids, or fewer than about 15 amino acids. In a particular embodiment, the peptides of the instant invention have more than about 5 amino acids, more than about 7 amino acids, or more than about 10 amino acids.
As stated hereinabove, the anti-microbial peptide of the instant invention may contain substitutions for the amino acids of the provided sequence. These substitutions may be similar to the amino acid (i.e., a conservative change) present in the provided sequence (e.g., an acidic amino acid in place of another acidic amino acid, a basic amino acid in place of a basic amino acid, a large hydrophobic amino acid in place of a large hydrophobic, etc.). The substitutions may also comprise amino acid analogs and mimetics. In a particular embodiment, the substitutions are predicted to promote helicity or helix formation.
The anti-microbial peptide of the instant invention may have capping, protecting and/or stabilizing moieties at the C-terminus and/or N-terminus Such moieties are well known in the art and include, without limitation, amidation and acetylation. The peptide template may also be lipidated or glycosylated at any amino acid (i.e., a glycopeptide). In particular, these peptides may be PEGylated to improve druggability. The number of the PEG units (NH2(CH2CH2O)CH2CH2CO) may vary, for example, from 1 to about 50.
The anti-microbial peptide of the instant invention may also comprise at least one D-amino acid instead of the native L-amino acid. The anti-microbial peptide may comprise only D-amino acids. In a particular embodiment, the anti-microbial peptides comprise D-amino acids which are spaced apart by about 1, 2, 3, and/or 4 (e.g., 3) consecutive L-amino acids.
The microbe-inhibitory peptides of the instant invention may contain at least one derivative of standard amino acids, such as, without limitation, fluorinated residues or nonstandard amino acids (e.g., beta-amino acids). In yet another embodiment, the peptide may also be circulated head to tail or locally involving a few residues.
The present invention also encompasses nucleic acids encoding the peptides and pharmaceutical compositions comprising at least one antimicrobial peptide of the instant invention and at least one pharmaceutically acceptable carrier (see below). The present invention also encompasses methods for preventing, inhibiting, and/or treating microbial infections (as explained hereinbelow). The pharmaceutical compositions of the instant invention can be administered to an animal, in particular a mammal, more particularly a human, in order to treat/inhibit/prevent a microbial (e.g., E. coli, MRSA, etc.) infection (e.g., the composition may be administered before, during, and/or after a microbial infection). The pharmaceutical compositions of the instant invention may also comprise at least one other antimicrobial agent (e.g., an antibiotic). The additional antimicrobial agent may also be administered in a separate composition from the antimicrobial peptides of the instant invention. The compositions may be administered at the same time or at different times (e.g., sequentially). The composition(s) comprising at least one anti-microbial peptide of the instant invention and the composition(s) comprising at least one additional antibiotic may be contained within a kit.
III. Nucleic Acid Molecules
Nucleic acid molecules encoding the anti-microbial peptides of the invention may be prepared by any method known in the art such as (1) synthesis from appropriate nucleotide triphosphates or (2) isolation and/or amplification from biological sources. The availability of nucleotide sequence information enables preparation of an isolated nucleic acid molecule of the invention by oligonucleotide synthesis. Indeed, knowledge of the amino sequence is sufficient to determine an encoding nucleic acid molecule. Synthetic oligonucleotides may be prepared by the phosphoramidite method employed in the Applied Biosystems 38A DNA Synthesizer or similar devices. The resultant construct may be purified according to methods known in the art, such as gel electrophoresis or high performance liquid chromatography (HPLC).
Nucleic acids of the present invention may be maintained in any convenient vector, particularly an expression vector. Different promoters may be utilized to drive expression of the nucleic acid sequences based on the cell in which it is to be expressed. Antibiotic resistance markers are also included in these vectors to enable selection of transformed cells. Anti-microbial peptide encoding nucleic acid molecules of the invention include cDNA, genomic DNA, RNA, and fragments thereof which may be single- or double-stranded. Thus, this invention provides oligonucleotides having sequences capable of hybridizing with at least one sequence of a nucleic acid molecule of the present invention.
Also encompassed in the scope of the present invention are oligonucleotide probes which specifically hybridize with the anti-microbial peptide nucleic acid molecules of the invention. Primers capable of specifically amplifying anti-microbial peptides encoding nucleic acids described herein are also contemplated herein. Such oligonucleotides are useful as probes and primers for detecting, isolating or amplifying anti-microbial peptide encoding nucleic acids.
IV. Uses of the Anti-microbial Peptides
The present invention also encompasses pharmaceutical compositions comprising at least one anti-microbial peptide of the instant invention and at least one pharmaceutically acceptable carrier. Such a pharmaceutical composition may be administered, in a therapeutically effective amount, to a patient in need thereof. The pharmaceutical compositions of the present invention can be administered by any suitable route, for example, by injection (e.g., parenteral, intramuscular, intravenous, or intraperitoneal administration), by oral, pulmonary, nasal, topical, or other modes of administration such as controlled release devices. The composition may be directly administered (e.g., by injection) to the site of microbial infection. In general, pharmaceutical compositions and carriers of the present invention comprise, among other things, pharmaceutically acceptable diluents, preservatives, stabilizing agents, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions can include diluents of various buffer content (e.g., saline, Tris HCl, acetate, phosphate), pH and ionic strength; and additives such as detergents and solubilizing agents (e.g., TweenTM 80, Polysorbate 80), anti oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). The compositions can be incorporated into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc., or into liposomes. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of components of a pharmaceutical composition of the present invention. Exemplary pharmaceutical compositions and carriers are provided, e.g., in “Remington's Pharmaceutical Sciences” by E.W. Martin (Mack Pub. Co., Easton, Pa.) and “Remington: The Science And Practice Of Pharmacy” by Alfonso R. Gennaro (Lippincott Williams & Wilkins) which are herein incorporated by reference. The pharmaceutical composition of the present invention can be prepared, for example, in liquid form, or can be in pill or dried powder form (e.g., lyophilized).
In yet another embodiment, the pharmaceutical compositions of the present invention can be delivered in a controlled release system, such as using an intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In a particular embodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. (1987) 14:201; Buchwald et al., Surgery (1980) 88:507; Saudek et al., N. Engl. J. Med. (1989) 321:574). In another embodiment, polymeric materials may be employed (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Press: Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley: New York (1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. (1983) 23:61; see also Levy et al., Science (1985) 228:190; During et al., Ann. Neurol. (1989) 25:351; Howard et al., J. Neurosurg. (1989) 71:105).
The present invention also encompasses methods for preventing, inhibiting, and/or treating microbial infections (e.g., viral or bacterial), particularly S. aureus infections (e.g., MRSA). The pharmaceutical compositions of the instant invention can be administered to an animal, in particular a mammal, more particularly a human, in order to treat/inhibit/prevent a microbial infection (e.g., the composition may be administered before, during, and/or after a microbial infection). The pharmaceutical compositions of the instant invention may also comprise at least one other anti-microbial agent, particularly at least one other antibiotic. The additional anti-microbial agent may also be administered in a separate composition from the anti-microbial peptides of the instant invention. The compositions may be administered at the same time and/or at different times (e.g., sequentially).
Bacterial infections that may be treated using the present methods include Gram-positive bacterial infection. In a particular embodiment, the bacteria is a staphylococcal strain. In yet another embodiment, the bacteria is Staphylococcus aureus. More particularly, the bacteria is MRSA.
The dosage ranges for the administration of the compositions of the invention are those large enough to produce the desired effect (e.g., curing, relieving, treating, and/or preventing the microbial infection, the symptoms of it, or the predisposition towards it). The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any counter indications.
V. Methods for Generating Anti-microbial Peptides
The instant invention also encompasses methods for generating anti-microbial peptides. In a particular embodiment, the method comprises 1) identifying a set of peptides having inhibitory activity against a microbe; 2) determining the most common length of the peptides within the set; 3) determining the most common amino acids (e.g., the most common 2, 3, 4, 5, or 6 amino acids (particularly the most common 4, 5, or 6 amino acids)) within the peptides within the set; 4) determining the most common net charge of the peptides within the set; 5) determining the most common range of hydrophobicity (e.g., within 5% ranges) of the peptides within the set; 6) determining the most common structure (e.g., α-helix, β-sheet, random, etc.) of the peptides in the set; and 7) designing the anti-microbial peptide which satisfies the criteria determined in steps 2) through 6). In a particular embodiment, the method further comprises identifying the most common motifs (e.g., 3 or 4 amino acid motifs) present in the peptides in the set and incorporating those motifs into the anti-microbial peptide. The methods may further comprise synthesizing the designed peptide and testing the peptide for the desired anti-microbial properties.
In one embodiment, the peptides may be obtained from the antimicrobial peptide database (aps.unmc edu/AP/main.html). In a particular embodiment, the anti-microbial activity of the designed peptide is compared to the anti-microbial activity of the peptides within the set. The anti-microbial activity of the modified peptides may be measured by any method, such as measuring the ability of the peptide to kill the microbe.
The following examples describe illustrative methods of practicing the instant invention and are not intended to limit the scope of the invention in any way.
EXAMPLE 1
Natural antimicrobial peptides (AMPs) represent excellent antimicrobial candidates (Wang, G. (2010) Antimicrobial Peptides: Discovery, Design and Novel Therapeutic Strategies, CABI, England). Candidates from the antimicrobial peptide database have been screened and several anti-HIV peptides have been identified (Wang et al. (2004) Nucleic Acid Res., 32:D590-D592; Wang et al. (2009) Nucleic Acids Res., 37:D933-D937; Wang et al. (2010) Antimicrob. Agents Chemother., 54:1343-1346). Here, an ab initio design of potent anti-MRSA peptides is provided. All the parameters (e.g. peptide length, charge, and amino acid composition) for peptide design from the beginning were determined by database filtering technology (DFT). DFTamP1, the first AMP designed using this technology, consists merely of four types of frequently occurring amino acids (glycines, leucines, lysines, and serines). The peptide caused bacterial surface damage and killed community-associated MRSA USA300 rapidly. Structural determination of DFTamP1 by NMR spectroscopy revealed an eight-leucine membrane-targeting surface essential for killing Gram-positive MRSA. A combination of ab initio design with database screen led to novel peptides with enhanced potency. The designed peptides are also attractive leads because of their simple composition, short length, stability to proteases, and membrane targeting. All these advantages of the designed compounds make them ideal novel anti-MRSA therapeutics.
Natural antimicrobial peptides (AMPs) are essential host defense molecules discovered in bacteria, plants, and animals (Zasloff, M. (2002) Nature 415:389-395; Hancock et al. (2006) Nat. Biotechnol., 24:1551-1557; Brogden, K. A. (2005) Nat. Rev. Microbiol., 3:238-250). These polypeptides can adopt a variety of three-dimensional structures and constitute excellent templates for engineering a new generation of antimicrobials. Numerous methods have been developed for peptide design (Wang, G. (2010) Antimicrobial Peptides: Discovery, Design and Novel Therapeutic Strategies, CABI, England). The first method is natural template optimization via truncation or substitution (Wang, G. (2008) J. Biol. Chem., 283:32637-32643; Monincova et al. (2010) Amino Acids 39:763-775). The second method is sequence shuffling, i.e. changing the positions of amino acids in the sequence. This spans from sequence reversal to combinatorial library, where all the residues may be optimized (Cherkasov et al. (2009) ACS Chem. Biol., 4:65-74; Merrifield et al. (1995) Proc. Natl. Acad. Sci., 92:3449-3453; Li et al. (2006) Biochim. Biophys. Acta, 1758:1203-1214; Monroc et al. (2006) Peptides 27:2575-2584). The third method is motif hybridization. Examples include early cecropin-melittin hybrids to recent “Grammar”-generated peptides (Merrifield et al. (1995) Proc. Natl. Acad. Sci., 92:3449-3453; Haney et al. (2012) Biochim. Biophys. Acta 1818:762-775; Loose et al. (2006) Nature 443:867-869). Finally, novel AMPs can also be de novo or rationally designed from a few amino acids (e.g. KL peptides) (Blondelle et al. (1992) Biochemistry 31:12688-12694; Kang et al. (2009) J. Pept. Sci., 15:583-588; Chen et al. (2005) J. Biol. Chem., 280:12316-12329; Mangoni et al. (2011) Cell. Mol. Life. Sci., 68:2267-2280).
Experimental Section
The Antimicrobial Peptide Database (aps.unmc.edu/AP/main.html)
To facilitate search, prediction, and design of AMPs, the APD was established in 2003 (Wang et al. (2010) Antimicrob. Agents Chemother., 54:1343-1346). The first version of the database contained 525 entries. The second version reported 1280 AMPs. As of February 2012, the updated APD registered 1954 AMPs. Natural peptides (<100 amino acids) will be collected into the database if their amino acid sequences and biological activity have been determined. The APD enabled a systematic search of peptide information, including peptide name, amino acid sequence, length, charge, hydrophobic content, structure, and biological activity. Users can search antibacterial, antifungal, antiviral (anti-HIV), anti-parasital, anticancer, spermicidal, insecticidal, and chemotactic data. These structure and activity filters in the APD provide a solid basis for this ab initio design.
Peptides and Hydrophobicity Measurements.
The peptides were chemically synthesized and purified (>95%) by GeneMed Synthesis, TX. One of the methods to estimate peptide hydrophobicity is to measure its retention time by HPLC (Chen et al. (2005) J. Biol. Chem., 280:12316-12329; Wang et al. (2012) Biochemistry 51:653-664). This was done on a Waters HPLC system equipped with an analytical reverse-phase Vydac C18 column (250×4.6 mm) The peptide was eluted by a linear gradient of acetonitrile (containing 0.1% TFA) from 5% to 95% at a flow rate of 1 ml/minute. The peptide peak was detected by UV at 220 nm.
Organisms and Antibacterial Activity Assays.
The bacterial strains used in the study are Bacillus subtilis 168, methicillin-resistant Staphylococcus aureus USA300 LAC (Gram-positive), Escherichia coli K12, and Pseudomonas aeruginosa PAO1 (Gram negative). The antibacterial activities of the peptides were determined using the standard broth microdilution method (Wang et al. (2005) J. Biol. Chem., 280:5803-5811). In brief, the bacterial culture (90 μL) was treated with a series of peptide solutions (10 μL), each with two-fold dilution. After overnight incubation at 37° C., the microplate was read on a ChroMate® 4300 Microplate Reader at 630 nm (GMI, Ramsey, Minn.). The MIC was defined as the lowest peptide concentration that fully inhibited bacterial growth.
Measurements of the Minimal Hemolytic Concentration.
Peptide hemolysis was assayed using an established protocol (Malmsten et al. (2011) PLoS One 6:e16400). In brief, fresh blood, obtained from the UNMC Blood Bank, was washed three times with PBS buffer and made into a 5% solution. To 90 μL of this solution, 10 μL of a peptide solution was added and incubated at 37° C. for one hour. After centrifugation at 13,000 rpm, aliquots of the supernatant were transferred to a fresh 96 well microplate. The absorbance of the solutions was measured at 545 nm to detect the amount of hemoglobin released. The percent lysis was calculated by assuming 100% release when treated with 2% Triton X-100 and no lysis (0%) when treated with PBS buffer. HL50 was the peptide concentration that caused 50% lysis of human erythrocytes. The cell selectivity (CS) indexes were calculated as the ratio of HL50 to the MIC of the peptide against S. aureus USA300.
Transmission Electron Microscopy.
S. aureus USA300 were grown in LB medium at 37° C. to the mid-logarithmic phase. Five mL of the culture was treated with the peptide DFTamp1 at 2× or 8×MIC for 1 hour. After washing with PBS, cells were fixed with a solution of 2% paraformaldehyde and 2% glutaraldehyde in 0.1 M PBS. The untreated control sample was processed in the same way. Ten μL of the bacterial suspension was adsorbed onto 200 mesh copper grids coated with formvar and silicon monoxide for 2 min, dried with the help of a blotting paper and then negatively stained by two drops of Nanovan® (Nanoprobes). Samples were observed in FEI Technai G2 TEM operated at 80 kV accelerating voltage.
Flow Cytometry.
Membrane permeation measurements were performed as described (Wang et al. (2012) Antimicrob. Agents Chemother., 56:845-856) using BacLightTM bacterial membrane potential kit (Molecular probes, Invitrogen) and a DNA-binding dye TO-PRO3 according to the manufacturer's guidelines on a FACSAriaTM Flow Cytometer (BD Biosciences, San Jose, Calif.).
NMR Spectroscopy.
The NMR sample (0.3 mL) contained 2 mM peptide, 80 mM deuterated sodium dodecylsulfate (SDS), and 10% D2O as the field-locking signal. The pH of the NMR sample was adjusted to 5.4. Spectra were recorded on a 600-MHz Varian INOVA NMR spectrometer equipped with a triple-resonance cryogenic probe with a z-axis gradient capability. A set of 2D spectra, including NOESY, TOCSY, DQF-COSY, and natural abundance HSQC spectra, was recorded with the 1H, 15N, and 13C carriers set at 4.77, 118.27, and 36.37 ppm, respectively. Thirty increments (128 scans) and 80 increments (256 scans) were collected for the 15N (spectral width 2,200 Hz) and aliphatic 13C (spectral width 12,000 Hz) dimensions, respectively. Chemical shifts were referenced as recommended (Markley et al. (1998) J. Biomol. NMR 12:1-23). Data were processed on a Silicon Graphics Octane workstation using NMRPipe (Delaglio et al. (1995) J. Biomol. NMR 6:277-293) and analyzed by PIPP (Garrett et al. (1991) J. Magn. Reson., 95:214-220).
Structure Calculations.
For structural calculations, major NMR restraints were derived from 2D NOESY spectra (Wüthrich, K. (1986) NMR of proteins and nucleic acids, Wiley, New York, N.Y.) and converted to distance restraints 1.8-2.8, 1.8-3.8, 1.8-5.0, and 1.8-6.0 Å corresponding to strong, medium, weak, and very weak types of NOE peaks, respectively. Backbone angles were predicted based on 1Hα, 15N, 13Cα, and 13Cβ chemical shifts as described (Wang et al. (2005) J. Biol. Chem., 280:5803-5811). An extended covalent structure was used as starting coordinates. In total, 100 structures were calculated using the simulated annealing protocol in the Xplor-NIH program (Schwieters et al. (2003) J. Magn. Reson., 160:65-73). Twenty structures were accepted and analyzed (Wang et al. (2012) Biochemistry 51:653-664).
Peptide Stability to Proteases.
Peptide stability was evaluated using standard SDS-PAGE (described in FIG. 5).
Results
Herein, a novel database-derived technology that enables one to design potent antimicrobials from the beginning is described. Peptide information in peptide databases allows users to effectively retrieve peptides with defined properties. In addition, peptides can be sorted according to key parameters such as length, charge and hydrophobicity. This feature makes it possible to locate the maximum in each case (FIG. 1, filled columns). These maxima represent the most probable parameters that determine the properties of natural AMPs. It is demonstrated here that these parameters can be merged to design novel peptides from the beginning. Because no assumption is taken in the design, this innovative approach is referred to as ab initio rather than de novo. A clear advantage of this ab initio approach is that the designed peptide is likely antimicrobial because it utilizes the most probable parameters of natural AMPs.
FIG. 1 depicts a pipeline of database search functions (or filters), each defining one parameter for the peptide. For short, this may be called pipeline database filtering technology. To illustrate this technology, novel compounds to combat Gram-positive bacteria (G+), especially MRSA, were designed due to its growing threat to the public health. At the time of the design, the activity filter selected 268 AMPs with anti-G+ activity from the APD. This set of AMPs was utilized as models to derive design parameters. To determine the peptide length, the number of peptides in a defined length group (step size 5) was plotted. The anti-G+ peptides with 11-15 residues were found to be dominant. A further analysis revealed that the majority of these peptides had a peptide length of 13 (FIG. 1B), which was thus determined as the most probable peptide length for the design. The third filter was used to determine the type of amino acids. To simplify the design, four representative amino acids (leucines, L; glycines, G; serines, S; and lysines, K) with the highest frequencies were selected (FIG. 1C). The general importance of G, S, and K can be appreciated from their high frequencies in the averaged amino acid profiles of 44 bacterial lantibiotics, 131 plant cyclotides, and 75 amphibian temporins (see FIG. 1G).
A fourth filter was introduced to determine the number of charged residues. A plot of peptide entries as a function of net charge showed that the largest anti-G+ group had a net charge of +1 (FIG. 1D), leading to the choice of one lysine. In addition to positive charge, hydrophobicity is another essential element in natural AMPs. Therefore, the hydrophobic content for the peptide was subsequently determined FIG. 1E showed that most peptides possessed hydrophobic contents in the 61-65% range, which corresponded to eight leucines for a 13-residue peptide. With one K and eight L residues determined, there were only four additional residues (G or S) to be assigned. Two G and two S amino acids were assigned owing to their similar frequencies in FIG. 1C. Taken together, this 13-residue peptide designed here comprised 1K, 2G, 2S, and 8L.
There are numerous ways of combining this set of residues into unique peptide sequences. To reduce the possibilities, additional filters were utilized. FIG. 1F presented structure distribution of the anti-G+ peptides with 11-15 residues. All the known structures were helical. Therefore, the sixth filter suggested a helical conformation for the designed peptide. The seventh filter was introduced to help one decide on the model to build the helix. To reduce the possible combinations, a structure filter was utilized. FIG. 1F presents the number of anti-G+ peptides that form different secondary structures. The dominance of the α-helical conformation in this group indicated a similar structure for the designed peptide. In general, there are two models for building an amphipathic helix. In the first model, all hydrophobic residues are clustered at one end and all hydrophilic residues at the opposite side. In the second model, hydrophobic residues are interspersed with hydrophilic residues at every 2-3 residues. The motif search function was utilized in the APD to help to decide on the helix model. Motifs are a cluster of amino acid residues that occur frequently in natural AMPs. Because there was no peptide in this database that contained four or more leucines in a row, it is unlikely that the eight leucines could all appear at one end of the peptide sequence. This allowed for rejection of the first model and the design of the peptide according to the second model. The construction of a unique peptide sequence in the helical family requires the use of the motif filter (FIG. 1A). Table 1 provides further details. As the combinations LL, LLL, and LLLL occurred in 449, 11, and 0 AMP sequences in the APD, respectively, it is best to split the eight leucines into four pairs (i.e. LL-LL-LL-LL). To place G, S, and K into this leucine pattern, we three residue motifs were compared and it was found that GLL, KLL, and SLL are all well represented in the AMP database (GLL, 147; KLL, 69; and SLL, 58). Alternatives such as LLG, LLK, and LLS were rejected to avoid the generation of a string of LLLL, which does not occur in the APD. If three 3-residue motifs (GLL, KLL, and SLL) are chosen, a 4-residue motif is also possible to reach the 13-residue limit. The frequencies of possible 4-residue motifs were compared and GKLL was found to have the highest occurrence in the database. This led to four highly occurring motifs GLL, SLL, SLL, and GKLL that match the amino acid composition of the designed peptide. Logically, two peptide sequences are possible depending on whether the four motifs are connected in ascending (increase in frequency) or descending (decrease in frequency) order. Sequence 1 was arranged in the ascending order GKLL(41)-SLL(58)-SLL(58)-GLL(147), whereas sequence 2 was assembled in the descending order GLL(147)-SLL(58)-SLL(58)-GKLL(41) (frequency in parenthesis). Random combinations were rejected because they are in conflict with the spirit of the “rational design.” Additional motifs were investigated that define the optimal connections between the above four motifs. There are three possible joints between the four motifs in each sequence. Two joints are identical (LL-S or L-SL) and only the C-terminal joints differ (LL-G or L-GL for sequence 1 and LL-G or L-GK for sequence 2). Because the linking motif LGK appeared more frequently in the database (89 counts) than LGL (31 counts), sequence 2 that contains LGK was thus established as the final sequence. Therefore, a novel peptide was obtained by selecting the most probable AMP parameters in each step of the design. The whole DFT pipeline arrived at the unique peptide sequence: GLLSLLSLLGKLL (SEQ ID NO: 1). This is the first antimicrobial peptide designed using DFT (hereinafter referred to as DFTamP1). This peptide is designed to target Gram-positive bacteria by adopting a helical conformation. Hereinbelow, proof for both structure and activity of DFTamP1 are provided.







TABLE 1







Database motifs and their


 application in peptide design.










Motifs
Maximum hits in the APD











I. The leucine motifs










LL
449



LLL
11



LLLL
0







II. The 3-residue motifs containing “LL”










GLL
147



LLG
75



SLL
58



LLS
90



KLL
69



LLK
58







III. The 4-residue motifs










GKLL
41



KGLL
6



GSLL
18



SGLL
19



GGLL
25



KSLL
7



SKLL
1



SSLL
1







IV. The joining motifs










LLG
75



LLS
90



LSL
37



LGL
31



LGK
89







Updated data were obtained from the antimicrobial peptide database (aps.unmc edu/AP) (total AMP entries: 1954). These hits changed little during the peptide design. Motifs incorporated into DFTamP1 were underlined.






The in vitro activities of DFTamP1 were assayed using the standard microdilution method (Wang et al. (2005) J. Biol. Chem., 280:5803-5811). The peptide was found to be active against S. aureus USA300 with a minimal inhibitory concentration (MIC) of 3.1 μM. However, the peptide did not inhibit the growth of B. subtilis, E. coli or P. aeruginosa until 120 μM (Table 2). In the presence of DFTamP1, the continuous and round surface of S. aureus USA300 (FIG. 2A) was damaged and cell leakage (blebs) was detected by transmission electron microscopy (FIG. 2B, arrow). This cell leakage agreed with the results of flow cytometry (FIG. 2C), because surface damage by the peptide enabled the entrance of the DNA-binding dye into bacteria, leading to a steep fluorescence buildup in 30 minutes. Rapid killing of MRSA USA300 is also supported by killing kinetics experiments (FIG. 2J). These results indicate that the peptide acted on bacterial membranes (Wang et al. (2012) Antimicrob. Agents Chemother., 56:845-856).







TABLE 2







Bacterial minimal inhibitory concentration (MIC), selectivity index and


hydrophobicity of database-derived anti-MRSA peptides.












Sequencea
MIC (μM)

tRP














Peptide
(SEQ ID NO)
SA
BS
EC
PA
CSb
(min)c

















DFTamP1
GLLSLLSLLGKLL
3.12
>120
>120
>120
3.3
19.79



(1)








 


DFTamP1-p
GLLPLLSLLGKLL
1.56
3.12
25
>100
1.3
18.716



(2)








 


DFTamP1-pi
GIIPIISIIGKII
>34
>30
>34
>30
 NAd
17.565



(3)








 


DFTamP1-pv
GVVPVVSVVGKVV
>100
>100
>100
>100
NA
12.364



(4)








 


Temporin-
FFGSVLKLIPKIL
3.12
6.25
25
>100
40
14.498


PTa
(5)








 


Temporin-
FFGSVLKLIPKIL
3.12
6.25
25
>100
NA
14.483


PTa (D-form)
(6)








 


Temporin-
FFGSLLKLLPKLL
0.78-1.56
3.12
12.5
50-100
32
15.393


PTa6L
(7)








 


Temporin-
LLGSLLKLLPKLL
0.78-1.56
3.12
12.5
>100
32
15.427


PTa8L
(8)








 


DASamP1e
FFGKVLKLIRKIF
3.12
>100
>100
>100
8
14.923



(9)





SA: S. aureus USA300; BS: B. subtilis; EC: E. coli K12; PA: P. aeruginosa.


aThe C-termini of the peptides are amidated.


bCell selectivity index of the peptide.


cThe HPLC retention time of the peptide.


dNot available.


eDatabase screening obtained antimicrobial peptide 1, which is a mutant of temporin-PTa (Conlon et al. (2008) Toxicon 52:465-473).






To provide insight into the mechanism of membrane targeting, the three-dimensional structure of DFTamP1 was determined in membrane-mimetic micelles (Wüthrich, K. (1986) NMR of proteins and nucleic acids, Wiley, New York, N.Y.). In addition to 2D homonuclear NMR data (FIG. 2D), a natural abundance heteronuclear 1H and 15N correlated NMR spectrum was recorded (FIG. 2E). The heteronuclear data were very helpful in this case because of a high content of leucines in the peptide (61.5%). The data enabled both the substantiation of spectral assignments and structural refinement (Wang et al. (2005) Biol. Chem., 280:5803-5811). DFTamP1 was found to adopt an amphipathic helical structure (FIG. 2F), where hydrophilic and hydrophobic side chains were clustered on opposite faces (FIG. 2G,H). The C-terminal amide protons formed hydrogen bonds with the carbonyl oxygen of residue L9 (FIG. 2I). Statistics of the structure is summarized in Table 3. The fraying N-terminus of DFTamP1 (FIG. 2F) is consistent with sharp spectral lines for residues L2 to S4 (FIG. 2D). These dynamic data implied that residues L5-L13 of the peptide were more important for membrane binding. Collectively, the experimental data substantiated both the structure and activity of DFTamP1.







TABLE 3







Structural statistics of the designed peptide DFTamP1 in complex with 


sodium dodecylsulfate micelles.








Structural restraints
DFTamP1











no. of NOE restraints (total)
99


intra-residue
38


sequential
38


short-range
23


no. of backbone anglesa
20


Structure and quality



helical region
3-12


backbone rmsd (Å)b
0.36


NOE-derived distance violations (Å)
0.3


dihedral angle violations (deg)
5


Ramachandran plotc



residues in the most favored region (%)
93.75


residues in the additionally allowed region (%)
3.75


residues in the generously allowed region (%)
2.50





aPredicted by the updated version of the TALOS program (Cornilescu et al. (1999) J. Biomol. NMR, 13: 289-302).


bCalculated by MOLMOL (Koradi et al. (1996) J. Mol. Graphics, 14: 51-55) when residues 2-20 of the accepted ensemble of 20 structures were superimposed.


cCalculated by Procheck (Laskowski et al. (1996) J. Biomol. NMR, 8: 477-486). Since ~94% of residues are in the most favored region, the structures have been determined to high quality.






Database analysis revealed that the sequence of DFTamP1 resembled amphibian temporins (Mangoni et al. (2011) Cell. Mol. Life Sci., 68:2267-2280), where position 3 is usually a proline residue (Table 4). When amino acid S4 was changed to a proline (i.e. DFTamP1-p), the peptide gained activity against B. subtilis and E. coli, underscoring the important role of this proline in determining the activity spectrum of the peptide (also cf. temporin-PTa and DASamP1, Table 2). To confirm the importance of the leucine surface of DFTamP1 (FIG. 2E) for bacterial targeting, the eight leucines were substituted with isoleucines or valines (Table 2). The isoleucine analog (DFTamP1-pi) was poorly soluble and showed no activity at the maximal concentration achieved. The valine analog (DFTamP1-pv) was also inactive. The results from real time bacterial killing confirmed that the valine analog was unable to kill MRSA even at a concentration 32-fold of the MIC of DFTamP1, while DFTamP1 showed killing at its MIC and bacteria were lysed and inhibited at 8-fold the MIC (FIG. 3). Thus, the leucine surface of DFTamP1 is critical for membrane targeting (FIG. 2H) and MRSA killing. The reduced activity of these peptide mutants could be attributed to a decrease in hydrophobicity (Table 2) (Chen et al. (2005) J. Biol. Chem., 280:12316-12329; Wang et al. (2012) Biochemistry 51:653-664).







TABLE 4







Sequence alignment, physical parameters and activity of the major types of Temporins. 

















SEQ


APD
Peptide
Sequence
Physical parametersb
Activity
ID
















ID
name
Alignmenta
AA
P
L
Pho
RK
G+/G−
NO





1534 
Temporin-SHf




8
0
1
75
1
Y/Y
10


 


 99
Temporin L




13
0
2
61
2
Y/Y
11


 


101
Temporin G




13
1
2
61
1
Y/Y
12


 


110
Temporin-1Lb




14
0
3
57
2
Y/N
13


 


 94
Temporin A




13
1
4
61
1
Y/N
14


 


 98
Temporin F




13
1
4
61
1
Y/Y
15


 


 97
Temporin E




13
1
5
61
0
Y/N
16


 


859
Temporin H




10
1
5
50
1
Y/N
17


 


858
Temporin D




13
1
6
61
0
n.f.b
18


 


 95
Temporin B




13
1
6
61
1
Y/N
19


 


100
Temporal K




10
1 
6
60
1
Y/N
20


 


 96
Temporin C




13
1 
7
61
0
Y/N
21


 


N.A.b
DFTamP1




13
0 
8
61
1
Y/N
 1





aLeucines (L) are shaded, prolines (P) are underlined, and positively


charged residues in italics. Alignment gaps (i.e. missing residues) are represented


with dashes (-).


bPeptide sequences, their physical parameters and activity data were


obtained from the APD. Additional information, including the original source, can be


obtained by searching each entry in the database as well. AA: number of amino acid


residues; P: number of prolines; L; number of leucines; Pho: percent hydrophobic


residues; RK, the sum of R and K residues; G+, activity against Gram-positive


bacteria; G−, activity against Gram-negative bacteria; Y, Yes; N, No; n.f.: not found;


N.A., not available.






To further test the importance of leucines, amphibian temporin-PTa was also used as a model peptide. The antimicrobial activity of temporin-PTa was not reported due to a limited amount of material (Conlon et al. (2008) Toxicon., 52:465-473). DASamP1, a temporin-PTa analog (Table 2), showed anti-MRSA activity both in vitro and in vivo. Here, it was found that temporin-PTa displayed an antibacterial spectrum comparable to DFTamP1-p. Furthermore, a D-form of temporin-PTa, consisting of all D-amino acids, was equally potent against MRSA, E. coli, and B. subtilis, substantiating a non-chiral bacterial target (Merrifield et al. (1995) Proc. Natl. Acad. Sci., 92:3449-3453). To mimic the leucine anchor of DFTamP1 (FIG. 2H), additional leucines were incorporated into temporin-PTa to obtain the 6L and 8L analogs (Table 2). These two leucine-rich analogs displayed improved antibacterial activity and retained a cell selectivity index of 32. In contrast, increasing positively charged residues did not improve peptide potency but reduced cell selectivity of DASamP1 (Table 2). Hence, mimicking the leucine anchor of DFTamP1 offers a useful strategy to enhance anti-MRSA potency.
In conclusion, potent anti-MRSA peptides were identified based on either database screening or ab intio design. The screen approach is costly due to the need to synthesize numerous peptides followed by antibacterial assays, whereas this DFT technology is cost effective since only the designed peptide was made. By combining these two database approaches, the anti-MRSA potency of the peptide was enhanced (MIC 0.78 μM) while retaining a cell selectivity index of 32. The practices not only uncovered the basics for peptide engineering but also led to the discovery of novel anti-MRSA candidates. Such peptides (Table 2) possess several attractive features. First, they have short sequences and simple amino acid compositions, allowing for cost-effective chemical synthesis. Second, membrane targeting of these peptides enabled us to synthesize an all D-amino acid analog, which showed equal antibacterial activities (Table 2) but superior stability to chymotrypsin. In FIG. 4, the band intensity of the D-form of the peptide changed little after 22 hour incubation, whereas the L-form was rapidly degraded in 2 hours. Third, a high hydrophobicity but low positive charge of these compounds constitutes another advantage because MRSA strains are known to deploy positive charges on their surface to evade the action of cationic AMPs (Andra et al. (2011) J. Biol. Chem., 286:18692-18700). Finally, the in vivo efficacy of DASamP1, an analog of temporin-PTa, in preventing biofilm formation in a mouse model is demonstrated herein. Therefore, these peptides are effective anti-MRSA drugs and also constitute useful templates for developing further anti-MRSA drugs. Note that partial database information was previously used to design novel antimicrobial peptides against E. coli (Wang et al. (2009) Nucleic Acids Res., 37:D933-D937) or HIV-1 (Wang et al. (2010) Antimicrob. Agents Chemother., 54:1343-1346; Wang et al. (2011) J. AIDS Clinical Res., S2:003). Therefore, the database tool can be harnessed to design novel antimicrobial agents against a variety of microbial pathogens.
EXAMPLE 2
Based on database screening, six antimicrobial peptides (Ascaphin-8, DASamP1, DASamP2, lycotoxin I, maculatin 1.3, and piscidin 1) were identified that are highly potent against methicillin-resistant Staphylococcus aureus (MRSA) USA300. Among them, DASamP1 (database screened AMP 1) displayed bacteria-specific killing of MRSA in vitro, but not Escherichia coli K12, Bacillus subtilis, or Pseudomonas aeruginosa. Maculatin 1.3 showed Gram-specific activity against only Gram-positive bacteria tested. In addition, DASamP2, ascaphin-8, piscidin 1, and lycotoxin I displayed a broad-spectrum activity against both Gram-positive and Gram-negative bacteria. This is the first study that documents the activity of lycotoxin I against MRSA USA300. In addition, DASamP1 demonstrated in vivo efficacy in a mouse model of catheter-associated MRSA biofilm infection, where early biofilm establishment was suppressed.
Naturally occurring antimicrobial peptides (AMPs) are universal host defense molecules that have remained potent throughout the years (Boman, H. G. (2000) Immunol. Rev., 173:5-16; Hancock et al. (1998) Trends Biotechnol., 16:82-8; Lehrer, R. I. (2007) Curr. Opin. Hematol., 14:16-21; Zasloff, M. (2002) Nature 415:359-365). The Antimicrobial Peptide Database (APD, aps.unmc.edu/AP/main.html) collects a variety of such peptides from bacteria, fungi, plants, and animals (Wang et al. (2004) Nucleic Acids Res., 32:D590-2; Wang et al. (2009) Nucleic Acids Res., 37:D933-7). These peptides have been shown to be selectively or broadly active against bacteria, fungi, viruses, and/or parasites. Because AMPs rapidly eliminate microbes usually via membrane disruption, it is difficult or rare for them to develop resistance (Epand et al. (1999) Biochim. Biophys. Acta., 1462:11-28; Kamysz et al. (2003) Acta Biochim. Pol., 50:461-9; Hancock et al. (1998) Trends Biotechnol., 16:82-8). As a consequence, these natural peptides constitute promising templates for developing a new generation of antimicrobial agents.
To identify potent templates against MRSA, a group of 30 peptides selected from the APD was screened (Table 5). These peptides were chosen based on the following properties: First, the peptides are relatively short (<25 amino acid residues) and do not contain cysteines, allowing for cost effective chemical synthesis costs. Second, the peptides have a net positive charge. Cationic peptides are generally more active than anionic peptides because bacteria possess negatively charged surfaces. Third, the peptides are linear. Fourth, they do not have reported toxicity to mammalian cells. Finally, their effects on MRSA USA300 have not been tested. A11 the peptides used in this study were synthesized chemically and purified to >95% (GeneMed, TX). The quality of these peptides was verified prior to antimicrobial assays by RP-HPLC and concentrations were determined by UV spectroscopy.







TABLE 5







Antimicrobial peptides and their MICs (μM) against S. aureus USA300 and


E. coli K12.










Name (source)
Peptide sequence (SEQ ID NO)
SA
EC













Metalnikowin I
VDKPDYRPRPRPPNM (22)
>100
>100


(insect)





 


Ranatuerin 9 (frog)
FLFPLITSFLSKVL (23)
50
>100


 


Mastoparan M
INLKAIAALAKKLL (24)
>100
25


(insect)





 


Hyposin-5 (frog)
FRPALIVRTKGTRL (25)
>30
>30


 


Apidaecin IA
GNNRPVYIPQPRPPHPRI (26)
>100
>100


(insect)





 


Drosocin (insect)a
GKPRPYSPRPTSHPRPIRV (27)
>100
>100


 


PGLa (frog)
GMASKAGAIAGKIAKVALKAL-NH2k (28)
25
25


 


Clavanin B
VFQFLGRIIHHVGNFVHGFSHVF (29)
>100
>100


(tunicate)





 


Buforin II (toad)
TRSSRAGLQFPVGRVHRLLRK (30)
>71
>71


 


Styelin A (tunicate)
GFGKAFHSVSNFAKKHKTA-NH2 (31)
>100
>100


 


Ponericin L2
LLKELWTKIKGAGKAVLGKIKGLL (32)
85
>25


(insect)





 


Spinigerin (insect)
HVDKKVADKVLLLKQLRIMRLLTRL (33)
>81
>81


 


Piscidin 1 (fish)
FFHHIFRGIVHVGKTIHRLVTG (34)
3.1
12.5


 


Pseudin 1 (frog)
GLNTLKKVFQGLHEAIKLINNHVQ (35)
>100
100


 


Misgurin (fish)
RQRVEELSKFSKKGAAARRRK (36)
>84
>84


 


Lycotoxin I (spider)
IWLTALKFLGKHAAKHLAKQQLSKL (37)
3.1
25


 


Parasin I (fish)
KGRGKQGGKVRAKAKTRSS (38)
>84
>84


 


Brevinin-2-related
GIWDTIKSMGKVFAGKILQNL-NH2 (39)
25
25


(frog)





 


Maculatin 1.3 (frog)
GLLGLLGSVVSHVVPAIVGHF-NH2 (40)
6.2
>100


 


Latarcin 3a (spider)
SWKSMAKKLKEYMEKLKQRA (41)
>100
>100


 


Plantaricin chainA
GAWKNFWSSLRKGFYDGEAGRAIRR
>38.9
>38.9


(bacteria)b
(42)




 


Ascaphin-8 (frog)
GFKDLLKGAAKALVKTVLF-NH2 (43)
3.1
12.5


 


Desertcolin 1 (frog)
GLADFLNKAVGKVVDFVKS-NH2 (44)
>100
>100


 


Melectin (insect)
GFISILKKVLPKVMAHMK-NH2 (45)
12.5-25
12.5-25


 


Isracidin (cow)
RPKHPIKHQGLPQEVLNENLLRF (46)
>100
>100


 


DASamP1
FFGKVLKLIRKIF-NH2 (9)
3.1
>100


(synthetic)c





 


DASamP2
IKWKKLLRAAKRIL-NH2 (47)
6.2
3.1


(synthetic)d





 


DASamP3
GWFDVVKHIAKRF-NH2 (48)
50
12.5


(synthetic)e





 


DASamP4
NLVSGLIEARKYLEQLHRKLKNRKV (49)
>92
>92


(synthetic)f





 


DASamP5
SLSRFLRFLKIVYRRAF-NH2 (50)
12.5
25


(synthetic)g





 


DASamP6h
IWLTALKFLGKHAAKHLAKQQL-NH2
3.1
12.5


(synthetic)
(51)




 


DASamP7i
IWLTALKFLGKHAAKHLL-NH2 (52)
1.6
12.5


(synthetic)





 


Temporin-PTa
FFGSVLKLIPKIL-NH2 (5)
3.1
NE


 


DASamP8j
FFGRVLRLIRRIF-NH2 (53)
6.2
NE


(synthetic)





SA: S. aureus USA300; EC: E. coli K12.


aResidue T11 is not O glycosylated.


bThe sequence of this peptide corresponds to chain A of plantaricin JK.


cA peptide mutant of temporin-PTa with S4K, P10R, and L13F mutations.


dA peptide mutant of polybia-MPI with the following mutations: D2K, D8R, and Q12R.


eThis peptide was obtained by changing the last three residues SAV of uperin 7.1 to KRF.


fThe sequence of this peptide corresponds to chain A of distinctin with residue C23 changed to R.


gA mutant of temporin-LTc with three mutations: S7R, P14R, and P15R.


hA mutant of lycotoxin I with C-terminal residues 23-25 deleted.


iA mutant of lycotoxin I with C-terminal residues 19-25 deleted and by changing A18 to L18.


jA analogue of DASamP1 where the K residues were replaced by R residues.


kThe C-terminal amidation is represented by NH2.






For the initial screen, antimicrobial activities of these peptides against S. aureus and E. coli were evaluated using the standard broth microdilution protocol (Wang, G. (2008) J. Biol. Chem., 283:32637-43). Table 1 lists the peptides and their MICs against E. coli K12 and S. aureus USA300. Six peptides, which are DASamP1, DASamP2, piscidin 1, lycotoxin I, maculatin 1.3, and ascaphin-8, were found to be active against S. aureus with an MIC in the range of 3.1 to 6.2 μM. Only two (DASamP1 and maculatin 1.3) of these six peptides failed to kill E. coli up to a concentration of 100 μM. Subsequently, the in vitro activity of these six peptides was evaluated against Bacillus subtilis and Pseudomonas aeruginosa (Table 6). While ascaphin-8, DASamP2, lycotoxin I, and piscidin 1 showed activity against both B. subtilis and P. aeruginosa, maculatin 1.3 was active against B. subtilis but not P. aeruginosa. Interestingly, DASamP1 was active against neither B. subtilis and P. aeruginosa. Taken together, it was concluded that ascaphin-8, DASamP2, lycotoxin I, and piscidin 1 are wide-spectrum AMPs that are active against all of the Gram-positive and Gram-negative bacteria tested here. While maculatin 1.3 is active against two Gram-positive but not two Gram-negative bacterial strains, DASamP1 is species-specific since it active only against S. aureus. The finding that ascaphin-8, maculation 1.3, and piscidin 1 are wide-spectrum AMPs agrees with the literature (Apponyi et al. (2004) Peptides 25:1035-1054; Conlon et al. (2004) Biochem. Biophys. Res. Commun., 320:170-175; Silphaduang et al. (2001) Nature 414:268-269; Souza et al. (2005) J. Immunol., 186:6585-6596). For lycotoxin I, it was previously found to active against Gram-negative E. coli and yeast (Yan et al. (1998) J. Biol. Chem., 273:2059-2066). This study, however, revealed its activity against Gram-positive S. aureus. There was no antibacterial data available for DASamP1, its wild-type peptide temporin-PTa (Conlon et al. (2008) Toxicon., 52:465-473) or DASamP2 (a peptide mutant of polybia-MPI (Souza et al. (2005) Peptides 26:2157-2164)) prior to the instant study.







TABLE 6







Antimicrobial and hemolytic activities 


of the six database-derived peptides.












Gram+ (μM)1
Gram− (μM)















Peptide
SA1
BS
EC
PA
HL502 (μM)
TI3
















DASamP1
3.1
>100
>100
>100
25
8


DASamP2
6.2
12.5
3.1
6.25
75
12


Piscidin 1
3.1
12.5
12.5
50
20
7


Lycotoxin I
3.1
6.25
25
25
125
40


Maculatin 1.3
6.2
25
>100
>100
25
4


Ascaphin-8
3.1
6.25
12.5
12.5
45
15





1Bacteria used are: SA, S. aureus USA300; BS, B. subtilis; EC, E. coli K12; and PA, P. aeruginosa. Bacterial minimal inhibitory concentrations are represented in MIC in μM.


2Concentration at which 50% red blood cells are lysed.


3Therapeutic index (TI) for S. aureus was calculated as HL50/MIC.






The hemolytic effects of the six peptides were also compared on human red blood cells (hRBC) using an established protocol (Malmsten et al. (2011) PLoS One 6:e16400). The hemolytic activity of these peptides is in the following order: piscidin 1>DASamP1 ̃maculatin 1.3>ascaphin-8>DASamP2>lycotoxin I. The therapeutic indexes (TI) of the six peptides were also calculated by taking the ratio between HL50 and the MIC of the peptide against S. aureus USA300 (Table 6). A high TI indicates good cell selectivity. Lycotoxin I was observed to have the highest TI of 40. DASamP1, DASamP2, ascaphin-8, and piscidin 1 have a TI of approximately 10.
Because bacterial species specificity is an important feature in order to exempt probiotic bacteria from the killing list, additional analogs of DASamP1 were synthesized. When all the lysines were changed to arginines, the activity of DASamP8 increased slightly (Table 5). As a comparison, temporin-PTa itself showed an identical activity against MRSA to DASamP1. This is the first documentation of antimicrobial activity for temporin-PTa. The effect of sequence truncation on antibacterial activity of lycotoxin I was also evaluated. Interestingly, the shortened peptides (DASamP6 and DAsamP7) showed similar anti-MRSA activity to the wild type. Thus, the peptides can be shortened while retaining activity.
DASamP1 was chosen for further efficacy testing in vivo because this novel peptide is short, easy to synthesize, and displayed species-specific activity. Bacterial specificity is an important consideration in the search for novel antimicrobials to prevent cidal activity against probiotic bacteria. The in vivo efficacy of DAPamP1 against MRSA USA300 LAC was examined using a mouse model of catheter-associated biofilm infection as previously described (Cassat et al. (2007) Methods Mol. Biol., 391:127-144; Rupp et al. (1999) Infect. Immun., 67:2627-2632; Thurlow et al. (2011) J. Immunol., 186:6585-6596). C57BL/6 mice (Day 3, n=16/group; Day 14, n=8/group) were infected with 103 colony forming units (cfu) of USA300 LAC::lux in the lumen of surgically implanted catheters to establish a biofilm infection Animals were treated with 200 μg peptide injected into the catheter at the time of infection (time 0) followed by 800 μg peptide delivered at four different sites surrounding the catheter at 24 and 48 hours post-infection. Bacterial titers associated with catheter or surrounding host tissue were evaluated at day 3 (FIGS. 5A, 5B) and day 14 (FIGS. 5C, 5D) post-infection to determine the impact of peptide treatment on bacterial burdens. Mice treated with DASamP1 exhibited a significant decrease in bacterial burdens associated with biofilm-infected catheters (FIGS. 5A, 5C) as well as surrounding tissues compared to vehicle-treated mice (FIGS. 5B, 5D). Collectively, these findings demonstrate that DASamP1 provides an effective means to prophylactically reduce MRSA colonization and biofilm formation on artificial surfaces in vivo.
In conclusion, six potent AMPs against MRSA USA300 have been identified by screening 30 peptides selected from the antimicrobial peptide database. This screening led to the identification of bacteria species-specific peptide DASamP1, Gram-positive specific peptide maculatin 1.3, and broad-spectrum peptides, including DASamP2, ascaphin-8, piscidin 1 and lycotoxin I. Therefore, these peptides represent effective antimicrobials as well as templates for developing further generations of antimicrobials against microbes such as MRSA. In particular, DASamP1, the first database screening-generated AMP against S. aureus, is novel, easy to synthesize, and showed a potent effect on MRSA. Such properties made DASamP1 attractive as a template for developing a new generation of antimicrobials against S. aureus. 
EXAMPLE 3
One of the hurdles in developing peptide-based antimicrobials is peptide stability to protease (Wang, G. (2010) Antimicrobial Peptides: Discovery, Design and Novel Therapeutic Strategies, CABI, England). To identify useful starting templates, we have developed a protocol that allows a simultaneous screening for antimicrobial activity as well as peptide stability. This was done by modifying the standard microdilution antimicrobial assays (Wang, G. (2008) J. Biol. Chem., 283:32637-32643). Specifically, the bacterial wells with a high peptide concentration (e.g. 100 μM) are duplicated (e.g., two for antimicrobial assays and two for protease stability assays). As an illustration, chymotrypsin was applied to the duplicated wells at a peptide:protease molar ratio of 25:1. Numerous peptides were screened in this manner. All the peptides were chemically synthesized using the solid-phase method and purified by HPLC to >95% (Genemed Synthesis, TX). The results of select peptides are provided in Table 7. KI-22 (Nell et al. (2006) Peptides 27:649-660) and GF-17 (Li et al. (2006) J. Am. Chem. Soc., 128:5776-5785) were found to be active against MRSA while GK-21 (Sigurdardottir et al. (2006) Antimicrob. Agents Chemother., 50: 2983-2989) was found to be weakly active against MRSA. Unfortunately, these peptides were degraded in the presence of chymotrypsin. However, the D-amino acid-containing GF-17 template (GF-17d3; Li et al. (2006) J. Am. Chem. Soc., 128:5776-5785) was resistant to the action of chymotrypsin as indicated by a successful suppression of the growth of E. coli K12 even in the presence of the protease.







TABLE 7







Screening for anti-MRSA peptides.













SAb

SEQ




MIC

ID


Name
Peptide sequence'
(μM)
Stabilityc
NO














KI-22
KIGKEFKRIVQRIKDFLRNLVP
10
−
54


 


GK-21
GKEFKRIVQRIKDFLRNLVPR
40
−
55


 


GF-17
GFKRIVQRIKDFLRNLV-amide
2.5
−
56


 


GF-17d3
GFKRIVQRIKDFLRNLV-amide
−
+
57





aUnderlined residues are D-amino acids.


bSA, S. aureus USA300.


cAll the peptides are active against E. coli K12. The sign “+” indicates the inhibition of E. coli growth even in the presence of chymotrypsin, where “−” indicates bacterial growth and peptide degradation.






As a consequence, GF-17d3 was chosen here as a template for developing anti-MRSA peptides. In the potential surface models of GF-17d3, a hydrophobic defect was more evident (FIG. 6). It was hypothesized that filling the hydrophobic defect with varying molecular moieties provides a practical approach to modulation of peptide activity. To test this hypothesis, different residues were utilized to replace the two F residues in A128A (Table 8). B128A was obtained by changing the first F of A128A to trifluoromethylphenylalanine. In C128A, however, the first F of A128A was substituted by biphenylalanine. In the case of D128A, both F's were replaced by biphenylalanine residues. Anti-MRSA assays showed that A128A was inactive (MIC>160 μM). However, both B128A and C128A gained activity against S. aureus USA300 with an MIC of 40 μM. D128A was most potent (MIC 5 μM) (Table 8). Likewise, anti-E. coli activity of the peptide series also increased (Table 8). Therefore, filling the hydrophobic defect with larger hydrophobic moieties indeed improved peptide activity against bacteria. In addition, the second F of A128A could also be altered to further enhanced peptide activity, although this mutation also increased the cytotoxicity of the peptide. In the case of A128A, B128A, and C128A, only 3-5% hemolysis was observed at 160 μM. D128A caused 50% lysis of red blood cells at 150 μM. These data could be converted to a therapeutic index, which equals hemolytic activity/MIC=150/5=30 for D128A. To understand the activity variation of these peptides, their retention times on a Waters reverse-phase HPLC system was also measured (Table 8). Because a longer retention time corresponds to higher hydrophobicity, the designed peptide became more hydrophobic from A128A to D128A (Table 8). It is proposed that the increase in antibacterial and hemolytic activity resulted from increased peptide hydrophobicity.







TABLE 8







Antimicrobial and hemolytic activity of the designed peptides.











Peptidea
E. coli K12
S. aureus USA
HL50
tR


(SEQ ID NO)
MIC (μM)
300 MIC (μM)
(μM)b
(min)














A128A (HC-15) (59)
10
>160
<3%
9.95


B128A (HC16) (60)
5
40
<5%
10.32


C128A (61)
5
40
<5%
10.55


D128A (62)
2.5
5
150
11.26





aThe A128A peptide (X1 = X2 = F) template, GX1KRLVQRLKDX2LRNLV-amide (SEQ ID NO: 58), was obtained by substituting isoleucines with leucines in GF-17d3. In addition, the three underlined leucines at positions 5, 9, and 13 are D-amino acids. Other peptides were designed by using different combinations of X1 and X2 residues (B128A, X1 = CF3-subtituted phenylalanine (F) and X2 = F; C128A, X1 = biphenylalanine and X2 = F; D128A, X1 = X2 = biphenylalanine).


bThe peptide concentration at which 50% human red blood cells were lysed.






Finally, the efficacy of the peptides was also shown in vivo. C57BL/6 mice received 4 injections (200 μg each) of D128A or PBS vehicle at 12, 24, and 48 hours following S. aureus infection, whereupon bacterial titers associated with infected catheters and surrounding tissues were quantitated at day 3 or 14 post-infection (FIG. 7). In both cases, the growth of the bacterium was entirely inhibited. These experiments demonstrate that D128A is also potent against MRSA in a mouse model.
In conclusion, D128A was engineered based on GF-17d3. D128A differs from GF-17d3 (derived from LL-37) by positions 17, 20, 24, and 27. These alterations improved peptide activity and reduced peptide production cost. By repairing the hydrophobic defect, D128A was found to be potent against both Gram-positive E. coli and Gram-positive MRSA USA300 both in vitro and in vivo. The broad-spectrum peptide showed a therapeutic index of 30.
A number of publications and patent documents are cited throughout the foregoing specification in order to describe the state of the art to which this invention pertains. The entire disclosure of each of these citations is incorporated by reference herein.
While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.

## Claims

1. An isolated anti-microbial peptide comprising the amino acid sequence GX1KRLVQRLKDX2LRNLV (SEQ ID NO: 58), wherein X1 and X2 are any amino acid.

2. The isolated anti-microbial peptide of claim 1, consisting of SEQ ID NO: 58.

3. The isolated anti-microbial peptide of claim 1, wherein the Leu at positions 5, 9, and 13 are D-amino acids.

4. The isolated anti-microbial peptide of claim 1, wherein X1 and X2 are hydrophobic amino acids.

5. The isolated anti-microbial peptide of claim 1, wherein X1 and X2 are biphenylalanine.

6. The isolated anti-microbial peptide of claim 1, which is SEQ ID NO: 62.

7. The isolated anti-microbial peptide of claim 1, wherein said peptide comprises at least one D-amino acid.

8. The isolated anti-microbial peptide of claim 1, wherein said peptide comprises at least one modification selected from the group consisting of amidation and acetylation.

9. A composition comprising at least one anti-microbial peptide of claim 1 and at least one pharmaceutically acceptable carrier.

10. The composition of claim 9, further comprising at least one antibiotic.

11. A method for inhibiting a microbial infection in a subject in need thereof, said method comprising administering to said subject the composition of claim 9.

12. The method of claim 11, further comprising the administration of at least one additional antibiotic.

13. The method of claim 11, wherein said microbial infection is a staphylococcal infection.

14. The method of claim 13, wherein said infection is a methicillin-resistant Staphylococcus aureus (MRSA) infection.